A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD

Dagmar Abelone Dalin*, Anders Løkke, Pernille Kristiansen, Charlotte Jensen, Kirsten Birkefoss, Hanne Rolighed Christensen, Nina Skavlan Godtfredsen, Ole Hilberg, Jeanett Friis Rohde, Anja Ussing, Charlotte Vermehren, Mina Nicole Händel

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

59 Downloads (Pure)

Abstract

Inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) has been debated for 20 years. In our systematic literature review and meta-analysis, we addressed the following: Should patients with COPD and a blood eosinophil count (EOS) of, respectively, a) < 150 cells/μl, b) 150–300 cells/μl, and c) > 300 cells/μl continue treatment with ICS? Protocol registered in PROSPERO (CRD42020178110) and funded by the Danish Health Authority. We searched Medline, Embase, CINAHL and Cochrane Central on 22nd July 2020 for randomized controlled trials (RCT) of ICS treatment in patients with COPD (≥40 years, no current asthma), which analyzed outcomes by EOS count and where >50% of patients used ICS prior. We used the GRADE method. Meta-analyzes for the outcomes were divided into EOS subgroups and analyzed for differences. We identified 11 RCTs with a total of 29,654 patients. A significant difference (p < 0.00001) between the three subgroups’ reduction of risk of moderate to severe exacerbation was found. Rate ratios for EOS counts: <150 cells/μL was 0.88 (95%CI: 0.83, 0.94); 150–300 cells/μL was 0.80 (95%CI: 0.69, 0.94); >300 cells/μL was 0.57 (95%CI: 0.49, 0.66). Overall, the certainty of the effect estimates was low to very low due to risk of bias, unexplained heterogeneity, few RCTs, and wide confidence intervals. A clear correlation was demonstrated between effect of continued ICS treatment (number of exacerbations, lung function, and quality of life) and increasing EOS count. Our meta-analyses suggested that treatment with ICS seemed beneficial for everyone except patients with EOS count below 150 cells/μl.

Original languageEnglish
Article number106880
JournalRespiratory Medicine
Volume198
Number of pages11
ISSN0954-6111
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors

Keywords

  • Blood eosinophils
  • Chronic obstructive pulmonary disease
  • Eosinophil
  • Inhaled corticosteroid
  • Pulmonary Disease, Chronic Obstructive/drug therapy
  • Adrenal Cortex Hormones/therapeutic use
  • Humans
  • Administration, Inhalation
  • Leukocyte Count
  • Disease Progression
  • Eosinophils

Fingerprint

Dive into the research topics of 'A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD'. Together they form a unique fingerprint.

Cite this